ARTICLE | Distillery Therapeutics
Therapeutics: Factor XIa
January 8, 2015 8:00 AM UTC
In vitro and rabbit studies have identified a phenylimidazole-based factor XIa inhibitor that could help treat thromboembolic disorders. In vitro, the lead compound reversibly inhibited factor XIa at subnanomolar Ki values. In a rabbit model of thrombosis, the lead compound decreased markers of thrombotic activity compared with no treatment. Next steps could include evaluating the factor XIa inhibitor in additional models of thromboembolic disorders...